JAMA ginkgo debate
This article was originally published in The Tan Sheet
Executive Summary
"Outcome trials should use cognitive tests that are sensitive to ginkgo's pharmacologic mode of action in the brain," say Pradeep Nathan, PhD, et al., Swinburne University of Technology, Australia, in Feb. 5 JAMA. Letter addresses recent study by Solomon et al. which found ginkgo caused no cognitive function improvement in healthy adults (1"The Tan Sheet" Aug. 26, 2002, p. 14). Nathan et al. suggest the selection of tests by Solomon et al. "may not be suitable to outcome studies of complementary therapies such as ginkgo, which generally produce only a mild to moderate benefit with continued use." Five letters appearing in JAMA challenge the study's blinding, focus on healthy individuals. Solomon et al. maintain their trial addressed manufacturer's claims, did not intend to take on herb's effects on impaired population...
You may also be interested in...
Ginkgo Study Shows “No Measurable Benefit” For Memory, Cognition
Daily doses of ginkgo biloba for six weeks resulted in "no significant difference for any outcome measure" versus placebo in approximately 200 adults over age 60 with healthy cognitive function in a study published in the Aug. 21 Journal of the American Medical Association.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.